Bausch Health Companies (BHC) Non-Current Deffered Revenue (2009 - 2012)
Bausch Health Companies (BHC) reported Non-Current Deffered Revenue of $36.1 million for Q4 2012, down 5.31% on a YoY basis from $38.2 million in Q1 2012, and down 1.63% sequentially from $36.7 million in Q3 2012.
Bausch Health Companies (BHC) Non-Current Deffered Revenue (2009 - 2012) Analysis & Trends
Bausch Health Companies (BHC) has 4 years of Non-Current Deffered Revenue data on file, last reported at $36.1 million in Q4 2012.
- For the quarter ending Q4 2012, Non-Current Deffered Revenue fell 5.31% year-over-year to $36.1 million; the trailing twelve-month figure through Dec 2012 stood at $36.1 million (down 5.31% YoY), and the FY2012 full-year result was $36.1 million, down 5.31% from the prior year.
- Non-Current Deffered Revenue fell to $36.1 million in Q4 2012, from $36.7 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $69.2 million in Q4 2009 to a low of $34.0 million in Q1 2012.
- A 4-year average of $45.5 million and a median of $42.0 million in 2011 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue declined 28.5% in 2011 and slipped 5.31% in 2012, its largest moves.
- Tracing BHC's Non-Current Deffered Revenue over 4 years: stood at $69.2 million in 2009, then dropped by 27.76% to $50.0 million in 2010, then slipped by 23.73% to $38.2 million in 2011, then slipped by 5.31% to $36.1 million in 2012.
- Business Quant data shows BHC's Non-Current Deffered Revenue at $36.1 million in Q4 2012, $36.7 million in Q3 2012, and $37.9 million in Q2 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 36.13 Mn |
| Sep 30, 2012 | 36.73 Mn |
| Jun 30, 2012 | 37.90 Mn |
| Mar 31, 2012 | 33.97 Mn |
| Dec 31, 2011 | 38.15 Mn |
| Sep 30, 2011 | 41.41 Mn |
| Jun 30, 2011 | 42.51 Mn |
| Mar 31, 2011 | 45.02 Mn |
| Dec 31, 2010 | 50.02 Mn |
| Sep 30, 2010 | 55.03 Mn |
| Jun 30, 2010 | 59.45 Mn |
| Dec 31, 2009 | 69.25 Mn |